Domain > hcp-da-pbsprep.tevapharm.com

More information on this domain is in AlienVault OTX

Whois

Property	Value
Email	domainadmincorp@teva.co.il
NameServer	NS4.TEVAPHARM.COM
Created	1996-06-14 00:00:00
Changed	2015-04-01 00:00:00
Expires	2016-06-13 00:00:00
Registrar	DOMAIN THE NET TECHN

DNS Resolutions

Date	IP Address
2025-04-16	172.64.146.173 (ClassC)
2025-09-20	104.18.41.83 (ClassC)

HTTP/1.1 403 ForbiddenDate: Sat, 20 Sep 2025 22:05:54 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: closeaccept-ch: Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UAcf-mitigated: challengecritical-ch: Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UAcross-origin-embedder-policy: require-corpcross-origin-opener-policy: same-origincross-origin-resource-policy: same-originorigin-agent-cluster: ?1permissions-policy: accelerometer(),autoplay(),browsing-topics(),camera(),clipboard-read(),clipboard-write(),geolocation(),gyroscope(),hid(),interest-cohort(),magnetometer(),microphone(),payment(),publickey-credentials-get(),screen-wake-lock(),serial(),sync-xhr(),usb()referrer-policy: same-originserver-timing: chlray;desc9824a07ff8201687x-content-type-options: nosniffx-frame-options: SAMEORIGINCache-Control: private, max-age0, no-store, no-cache, must-revalidate, post-check0, pre-check0Expires: Thu, 01 Jan 1970 00:00:01 GMTServer: cloudflareCF-RAY: 9824a07ff8201687-PDXalt-svc: h3:443; ma86400

!DOCTYPE html>html langen-US>head>title>Just a moment.../title>meta http-equivContent-Type contenttext/html; charsetUTF-8>meta http-equivX-UA-Compatible contentIEEdge>meta namerobots contentnoindex,nofollow>meta nameviewport contentwidthdevice-width,initial-scale1>style>*{box-sizing:border-box;margin:0;padding:0}html{line-height:1.15;-webkit-text-size-adjust:100%;color:#313131;font-family:system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji}body{display:flex;flex-direction:column;height:100vh;min-height:100vh}.main-content{margin:8rem auto;padding-left:1.5rem;max-width:60rem}@media (width  720px){.main-content{margin-top:4rem}}.h2{line-height:2.25rem;font-size:1.5rem;font-weight:500}@media (width  720px){.h2{line-height:1.5rem;font-size:1.25rem}}#challenge-error-text{background-image:url(data:image/svg+xml;base64,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);background-repeat:no-repeat;background-size:contain;padding-left:34px}@media (prefers-color-scheme: dark){body{background-color:#222;color:#d9d9d9}}/style>meta http-equivrefresh content360>/head>body>div classmain-wrapper rolemain>div classmain-content>noscript>div classh2>span idchallenge-error-text>Enable JavaScript and cookies to continue/span>/div>/noscript>/div>/div>script>(function(){window._cf_chl_opt  {cvId: 3,cZone: hcp-da-pbsprep.tevapharm.com,cType: managed,cRay: 9824a07ff8201687,cH: tdzX_pWqafnxdRgfT54Ok.hiAOiIjMlYMF0Q.NYxDDU-1758405954-1.2.1.1-6BjvirqgIltLpsUDpyRmfXNaXrnGr2ynyIZSe3HSnw17h7HI8bG7BEMBg4jSIbWH,cUPMDTk:\/?__cf_chl_tk0jCwoPxYWIyYj2jXpejUMm680jDxdtTDnGLK5DTWmgI-1758405954-1.0.1.1-ad0erRv8XsL2KJbl4QJM5Gq.Cx8sw.1vS4N3_oAnBvk,cFPWv: g,cITimeS: 1758405954,cTplC:0,cTplV:5,cTplB: cf,fa:\/?__cf_chl_f_tk0jCwoPxYWIyYj2jXpejUMm680jDxdtTDnGLK5DTWmgI-1758405954-1.0.1.1-ad0erRv8XsL2KJbl4QJM5Gq.Cx8sw.1vS4N3_oAnBvk,md: YEPjMy7fm.02Oa.sI0D07JVJupGx1o4kXUTwDbGn_sU-1758405954-1.2.1.1-e5o1BhHJDfH69DmTcV8zz3akMMIYUsoe9NB9ULcD.uDuMymNi6HvHG8hcenzElsdI3L22X9a0PwcinT28y_DVKEewJfKAC.YVOCCsk8hGPOjc0YX7lJqGV6l.wM.B.g711.1XTwtVjBKi6rVePQiqNaykt9vlaJLZnEhqAxAVYdhCGf.T4QGtPznBRRS7oZLwGHifjv8j2snUWEEaUE0xjftNmtVAPleTZe9R2mIgbxHexfl0JNGU9CTCm7Lc5kGhkahIF0bgF4JEnUyUx_WvQ0G8qrKUkhatbLKHuBKkOlRpWLGkWuGYb_h7mfvMVsfmuTPCs5Cv_PrAi8oE52XaiLQffj1s7M5D4uKv7C.DOEZW04zHl2WZ.bneefXomC7v9uEV4hqwNoMgdUNfnE9_ZxZ59Ueh3gujtHoRu56zBK2jVa.hSzNyVpLOyxKbVE4rK8BukbIBsbxFJU6sdBguYpiYjVwXSBguSfdgpURFxx33WFAYYwHA..48wLCVB5qL9Y1iyK.2Frk85M.ZE1Cp9cNNPqiJR7vyT6U5x03QjfVeno0SVzFiDqikc1tRmXozMjuAcV.nKA_8rH8.T3A28k7OOh7ggu_Pm3F15WqX9QtI_kc.2wo9eZz46sy8UWJwwkWkoVl0SgayXsbwhRt8h_D6neNEIg11MxPErpxVuuHHONA.RUf3IrCcK8adrzSg5GzIzUsJjlJnNAynZLF8la4yxR8x8581JUPFlDqsC_EEL3y5wPOSk0UmbQ1G2uU05ZhqVApC5InWSuEzopwd8fodHTdkvQ6RQwLgkJXUQ1Z3wtaRfuEhjYs91HYfK80wiMD3_OgJwipYLyKHcJLz99vnx6GOC3cU60xTdeyDDjKucSs60YWjH1qCPf8fnOMNP5L65HeYCp0Kkkg_tG9i_fyPnMuAwKZKHxkuu1lu6yr0PfylvD69CAPWcq4rqPX,mdrd: w2thP9IS_VKLQ1FwtzC1Ab0QAZuGmWaT2Nbgmr_ghBs-1758405954-1.2.1.1-MbOw3PB_Ss_BaMGLHp6JnHn2.6qWQTlNMuopfTiYDUXMe7ulRmw0PdNbdgKh9EhCVjfrWtf4_4ysrp7msg6CQHQwkST9CMQqQGxbStHkuN2RC_u7lTmUiNOe6isPt3uw2SIN1oLeAipNL_xSSm425WPaK_QTIfLPU1EGxe7zoWKm7mUzucu8HUA7FzcRj9l.YGdq515tWOonzqPn6zZOhKmOxJWnNwxOhRblFUYBqq16KCggZjSffbJK5cMBiMxZ4QSW7WXtSjM4cKFew85rhZuH5HQ0OchlzpJsfa_8n30M9hXxVgl6HoHF__e.Pb3_s1dRykxVbHNgaoAiq9WNEeeFOmqjzEQu33sHQ5X1T.f6k1EKw0qboo9Ec9CHu_bYq9hBI5qr2uXeW31NNf3Q0ksdEO9cdt7E7rGO_baI3YoAhWFs0P_OLeAYdhLp3f_llR7trfTQg.QdrnC4Y6fAr_LiXLMvx7FBy0XSmPYHA0EJznY3f_ngDnnEZxKWnwaxbUsbsSfNn0_3_Ng3Tyo80ta5pp9o8Xihn8cqyiew21yM1dNDIcCx804Ej.G5z_mx,};var a  document.createElement(script);a.src  /cdn-cgi/challenge-platform/h/g/orchestrate/chl_page/v1?ray9824a07ff8201687;window._cf_chl_opt.cOgUHash  location.hash   && location.href.indexOf(#) ! -1 ? # : location.hash;window._cf_chl_opt.cOgUQuery  location.search   && location.href.slice(0, location.href.length - window._cf_chl_opt.cOgUHash.length).indexOf(?) ! -1 ? ? : location.search;if (window.history && window.history.replaceState) {var ogU  location.pathname + window._cf_chl_opt.cOgUQuery + window._cf_chl_opt.cOgUHash;history.replaceState(null, null,\/?__cf_chl_rt_tk0jCwoPxYWIyYj2jXpejUMm680jDxdtTDnGLK5DTWmgI-1758405954-1.0.1.1-ad0erRv8XsL2KJbl4QJM5Gq.Cx8sw.1vS4N3_oAnBvk+ window._cf_chl_opt.cOgUHash);a.onload  function() {history.replaceState(null, null, ogU);}}document.getElementsByTagName(head)0.appendChild(a);}());/script>/body>/html>

Port 443

HTTP/1.1 403 ForbiddenDate: Sat, 20 Sep 2025 22:05:54 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: closeaccept-ch: Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UAcf-mitigated: challengecritical-ch: Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UAcross-origin-embedder-policy: require-corpcross-origin-opener-policy: same-origincross-origin-resource-policy: same-originorigin-agent-cluster: ?1permissions-policy: accelerometer(),autoplay(),browsing-topics(),camera(),clipboard-read(),clipboard-write(),geolocation(),gyroscope(),hid(),interest-cohort(),magnetometer(),microphone(),payment(),publickey-credentials-get(),screen-wake-lock(),serial(),sync-xhr(),usb()referrer-policy: same-originserver-timing: chlray;desc9824a0807946efb4x-content-type-options: nosniffx-frame-options: SAMEORIGINCache-Control: private, max-age0, no-store, no-cache, must-revalidate, post-check0, pre-check0Expires: Thu, 01 Jan 1970 00:00:01 GMTServer: cloudflareCF-RAY: 9824a0807946efb4-PDXalt-svc: h3:443; ma86400

!DOCTYPE html>html langen-US>head>title>Just a moment.../title>meta http-equivContent-Type contenttext/html; charsetUTF-8>meta http-equivX-UA-Compatible contentIEEdge>meta namerobots contentnoindex,nofollow>meta nameviewport contentwidthdevice-width,initial-scale1>style>*{box-sizing:border-box;margin:0;padding:0}html{line-height:1.15;-webkit-text-size-adjust:100%;color:#313131;font-family:system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji}body{display:flex;flex-direction:column;height:100vh;min-height:100vh}.main-content{margin:8rem auto;padding-left:1.5rem;max-width:60rem}@media (width  720px){.main-content{margin-top:4rem}}.h2{line-height:2.25rem;font-size:1.5rem;font-weight:500}@media (width  720px){.h2{line-height:1.5rem;font-size:1.25rem}}#challenge-error-text{background-image:url(data:image/svg+xml;base64,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);background-repeat:no-repeat;background-size:contain;padding-left:34px}@media (prefers-color-scheme: dark){body{background-color:#222;color:#d9d9d9}}/style>meta http-equivrefresh content360>/head>body>div classmain-wrapper rolemain>div classmain-content>noscript>div classh2>span idchallenge-error-text>Enable JavaScript and cookies to continue/span>/div>/noscript>/div>/div>script>(function(){window._cf_chl_opt  {cvId: 3,cZone: hcp-da-pbsprep.tevapharm.com,cType: managed,cRay: 9824a0807946efb4,cH: 2HqruxIKCpLKrPdqfiTtmAP2.aiazQ1hC4infxxmuPI-1758405954-1.2.1.1-EdJfmOmaLxLKPiAmLwc9dx4pJv7U14wI8VJX.4OftGJSlSuT.QynDS0l8NFePe19,cUPMDTk:\/?__cf_chl_tk5VJu1NV_wapGlGSA2ZFHdp3BJ3p73HTeGhiGBirM5eg-1758405954-1.0.1.1-16RTASvMgO1kWgcZ1Is432VeevcS9q_C7IvZuTiT.RI,cFPWv: g,cITimeS: 1758405954,cTplC:0,cTplV:5,cTplB: cf,fa:\/?__cf_chl_f_tk5VJu1NV_wapGlGSA2ZFHdp3BJ3p73HTeGhiGBirM5eg-1758405954-1.0.1.1-16RTASvMgO1kWgcZ1Is432VeevcS9q_C7IvZuTiT.RI,md: isNlMxbyMjZaZgJ3hEKlwicjJzSp10Sd8vsGUhxo_3w-1758405954-1.2.1.1-Up7qpvBFzRJvGNAv5A98MZkMUeYn548W2pduaIY1kq72qP7QvSQ7HoQn0oh.Jw4Mj_xQuORguMVDVEwWfsnfuO5uP_zyLJ5a6TyohxNR9XKcSmagFx8SC9tGaOmjphJk1Dq2Q8jPL.EjojhlxewkUkKV6kosCdTSBV1QhXdwlSvsnblzLZ74_99Vyoc5uvrbIyxZQlW3xrpEtAg7TTaMcL.fhpZNhLLUtSpUOnLTjqx5ccAUcaamYKrfHc4YrdGaFERsCSQUHa5rFJvc__oMGpSAlPUdf09FADGJttsnFlb6zY_RVR2acN0BPBzlQOu1nF.5RDACHToeC_2iT2VD21y4mNBtpVCSvOk7oRTwKdMzUTKsh3nQeqZCcJEWYW4gFvKfsdEsm9tfJbZG2rDkPOjZDbC7rPSnhxrNXuqsasbtQ97psEle.zbxXuKJIEmhfgu80c3WMNiSEoUL.ZAeu7OPO9zfiTkOhtXGYb1GEREcBW4MrTSGRrS1QBeIlmSnL0NvpR4yb3bk4EsVFdVAvI5Hu5cygt99yrsWbU2Bq8M6HRTwJKcwAqhfwQLE_0qCe4SIxWSNbCWPagwxTPH0KpHeHb2UFHB.KJAEo9q7SiUzLKJihlY1UIAjVgWuYvf4ym9qtH874xqbfrCv6ZWn.DBGSTRxWvPh.WNAg7rAwdqYBeZUS6TyfGng.MrJDccsQNkIFYGA5ZtHdEFEzW.feuIbfg.JS1yZNOwqAYonCTR7Tvk85MX5wT6x.aQ7RnG79VPjam.DRNXfjQ23.HbjRE9CdZhbi.0sfLaMOaCfkOqEh4IUqdC4GBiT2Qb5MEynBQRqrYQPvQqG226yUUrd0HcAwfkLYyYWGSWV2PH0zi26LwabvMc.yUPLP1h_0ptYl5lyi27BMymp9quTYHlV1Vw6PKDPDC1apmuKCGgUh8glA76_zie3zeUgby1Se6TR,mdrd: AEenxCNXWelYOM7rUm6rycjUtIX6cYvDywy_aOX6Zas-1758405954-1.2.1.1-0vR0PxKrt9mSKQyNWL_eR3r0jjUEAigk.keFgf7f1z8WoxuS_t8u6KoWVbJEV.ozKpnFPDQrDJUQhN1Xg4JqkZ216b0V6LCcUcBiIA3SIqJ9IylSzdZve_S7lCo_QVV3BjdFmyefOsIf2hKB7p7Qe7FTrcdmTaQVGiPZVdxIgfSeqESWRGUkYJwcA7OvA2CHoafBibqP_kwDsemkpzDjtre_2CJWvr6xV71Mj3EQpI.SDO_oOu2A1xMe1QbtQN3MnGP8XHcxp6knQzCwRVvXN8f47MDPD74fvG8C9g6X2TtmLK0SecXT17.kiB8tqw01ACm10PhjxzWnKZLMjh5tDaSrUjxRajwwylF0OyftPqDdw8rdkUoJlsIVxn75DOlLkrjgjUPECC0DH0WRBEWtSWu8kAcw47SgJTzxqFoKcgRDEa8F8WA07_S3keis0.2zZsT_62REQ8uYTux2Ubgy.ceJHQjkMYHYagiMWhj6pYUABT6XYoRvECPUvgs50fHrA9TaESoOY2v1pm1DUSttxStwMmwASBNBgql4nY3I6NVgDs56SNwNaefNHx.VwxbMT98umAkopxeYglgeQqDvWdxC5lBebYLxcJJfPRANPHvUng_15WyknA7s6JlhYDqwnD4JIVoBF1w_omy4PIUZkjiqBxP.P6iDH.HgGdYlpBImpTmHZemwAX5OE8uk8sjWUEgNZLF6Q4AeKMhdkq.BgrwKynS13TACiUgRPhxlo8kl.wWBapx28qdKjy7v53hwlBX3dpXzmsVcmNz1vmz45C6cTS2O86PYxURQqmj.EMSLrNEzYzR8TSoPNGSg.700Cvephqh7a.tC7NUnkaK7GdtbVB_3Uzx0cge_.owNA0uL0NX2_lWTsuii52k0wyrDK13qBlFJnLVjVRU2xbpOJIjsUMgxJz3A7h0I1QSd07JCGY8aPADpZok6HOj1Uw2okbhkSC1HTEYjmvUkn_nlBN5A9MyFAhfkF.pHiqwQzaUQ_12LyqCRl63bzHpG6XdF.Lxe5PiuYyqlax2XDzgW5nz6pyuFXp6ZItZe2yft..vY5eAFVJahFg5jXneLTG98k5j84omPwnzehHCbNEhbcCGp6P5F8HKtdmx8NdchKEDGeVIcwuqy7KLJrLZcgFrt3Ns8a2TbjHPitk2SsDB2qWNY7B6R0rt0jchW5WdCM2cTJV5cyoN2OJaVZmZv.zvEN9DBCY1SIDEj4_12h08lw.nUlX2nq2p4ck0cCONQS.B5NpWUJFedNma977wy_tgGwGOpfbRnlRe4QbekLyMG17ZzojBp6RKYmNPZZH55ULLB1zD3iiXNUk7XwlxN3K02DYDyavAVGEeNoOb79UMcE0xXjBz9YXBcSY75Oe1UlsNVF.n_7P5rbhRFY8KtI4hTYhaQqGFcu49_uphK71fljqVSG3ragDDfYAr39UiXj6NlFi1Mt6_DvU6h8YX8HyLrhbKxuxm48t46so0IB26wq.TzXLU5uEYT6EoGpRHPg3tXAz4QizcdncVzU12utUfKO0O.DvyLsmbSdqSTjB1gwr18r2Fa58EqnDnrcgauuxxzL95SM3fsC6HhEMAGkm5QUOojb37KWqOmtNaAZfErZkyO9EhGUCSzZmn9poUbmSFqYUwTtgHSMiwX5mGeVvhIkXl4rRzJyhYeSKM3hgUir8St1QdqmoxLGMyltBMBFoAOBhb07zZLVQNllmUtTIooxkZJ6aCUVtrkPNW1Veuh79vaDUmAjSs2orWz5mcIWFZo1vK71sRkEZmTv.PmCRsLrr1uS9N8udSuTRZ90IGZFap0Oq6JNM6nrgp3AyZ7vbbxUW7UDqjRFX84CjCWKTkw2Sy.FjsR6sb.BTLsIWEeVnCk20yWHcNO6E07CXkBoTgaKcZ.iqTZ.whtgDXdW18GnEz.kPj1wWF5jQHhg_EoEA,};var a  document.createElement(script);a.src  /cdn-cgi/challenge-platform/h/g/orchestrate/chl_page/v1?ray9824a0807946efb4;window._cf_chl_opt.cOgUHash  location.hash   && location.href.indexOf(#) ! -1 ? # : location.hash;window._cf_chl_opt.cOgUQuery  location.search   && location.href.slice(0, location.href.length - window._cf_chl_opt.cOgUHash.length).indexOf(?) ! -1 ? ? : location.search;if (window.history && window.history.replaceState) {var ogU  location.pathname + window._cf_chl_opt.cOgUQuery + window._cf_chl_opt.cOgUHash;history.replaceState(null, null,\/?__cf_chl_rt_tk5VJu1NV_wapGlGSA2ZFHdp3BJ3p73HTeGhiGBirM5eg-1758405954-1.0.1.1-16RTASvMgO1kWgcZ1Is432VeevcS9q_C7IvZuTiT.RI+ window._cf_chl_opt.cOgUHash);a.onload  function() {history.replaceState(null, null, ogU);}}document.getElementsByTagName(head)0.appendChild(a);}());/script>/body>/html>

Subdomains

Date	Domain	IP
tws01.tevapharm.com	2025-07-22	45.60.152.158
mx01.tevapharm.com	2013-05-16	192.115.248.100
eudigital02.tevapharm.com	2025-07-03	45.60.122.67
mx02.tevapharm.com	2014-04-25	192.115.251.27
ns3.tevapharm.com	2025-09-08	199.7.68.228
ns4.tevapharm.com	2025-09-19	199.7.69.228
ns5.tevapharm.com	2025-06-21	204.74.114.228
sfc.tevapharm.com	2025-09-09	45.60.151.76
us.sfc.tevapharm.com	2025-06-28	45.60.152.158
eu.sfc.tevapharm.com	2025-07-16	45.60.152.158
genuse.tevapharm.com	2025-07-01	45.60.152.158
www.genuse.tevapharm.com	2025-07-08	45.223.137.231
aktivmitms-ch-de-pbsinte.tevapharm.com	2025-06-30	172.64.146.173
ajovyde-pbsinte.tevapharm.com	2025-06-19	104.18.41.83
digihaler-uk-pbsinte.tevapharm.com	2025-09-20	172.64.146.173
ajovy-uk-pbsinte.tevapharm.com	2025-07-02	172.64.146.173
ajovy-il-pbsinte.tevapharm.com	2025-06-19	172.64.146.173
aviomarin-pl-pbsinte.tevapharm.com	2025-07-01	172.64.146.173
ajovyca-en-pbsinte.tevapharm.com	2025-06-20	172.64.146.173
liberize-en-pbsinte.tevapharm.com	2025-09-20	172.64.146.173
alvaiz-en-pbsinte.tevapharm.com	2025-05-24	172.64.146.173
ajovy-ca-fr-pbsinte.tevapharm.com	2025-05-23	104.18.41.83
aktivmitms-ch-fr-pbsinte.tevapharm.com	2025-05-25	104.18.41.83
ajovygr-pbsinte.tevapharm.com	2025-06-22	172.64.146.173
ajovy-ir-pbsinte.tevapharm.com	2025-05-21	104.18.41.83
kopf-klar-at-pbsinte.tevapharm.com	2025-09-01	172.64.146.173
selfcare-it-pbsinte.tevapharm.com	2025-09-20	104.18.41.83
tws01-dev-onboarding.tevapharm.com	2025-05-21	45.223.137.231
tws01-dev-catalog.tevapharm.com	2025-07-14	45.223.137.231
general.tevapharm.com	2024-04-20	13.107.213.70
hcp-da-pbsprep.tevapharm.com	2025-09-20	104.18.41.83
copaxone-de-pbsprep.tevapharm.com	2025-09-20	172.64.146.173
aktivmitms-ch-de-pbsprep.tevapharm.com	2025-06-22	172.64.146.173
ajovy-uk-pbsprep.tevapharm.com	2025-08-12	172.64.146.173
ajovy-il-pbsprep.tevapharm.com	2025-07-02	104.18.41.83
aviomarin-pl-pbsprep.tevapharm.com	2025-05-26	104.18.41.83
ajovyca-en-pbsprep.tevapharm.com	2025-05-26	104.18.41.83
teriparatide-en-pbsprep.tevapharm.com	2025-09-20	172.64.146.173
alvaiz-en-pbsprep.tevapharm.com	2025-05-26	172.64.146.173
aktivmitms-ch-fr-pbsprep.tevapharm.com	2025-05-26	104.18.41.83
ajovygr-pbsprep.tevapharm.com	2025-06-24	172.64.146.173
ajovy-ir-pbsprep.tevapharm.com	2025-06-01	104.18.41.83
wti-clinical-trials-es-pbsprep.tevapharm.com	2025-09-19	104.18.41.83
tws01-pp.tevapharm.com	2025-06-21	45.223.137.231
ir.tevapharm.com	2014-04-16	165.254.206.89
hcpportals.tevapharm.com	2025-07-09	45.60.122.67
status.tevapharm.com	2025-08-19	13.69.68.44
tws01-dev-content.tevapharm.com	2025-07-02	45.223.137.231
qa1.tws01-dev-content.tevapharm.com	2025-07-24	45.223.137.231
tws01-int.tevapharm.com	2025-08-26	45.223.137.231
www.tevapharm.com	2024-11-25	45.60.151.76

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > hcp-da-pbsprep.tevapharm.com

Is this malicious?

Whois

DNS Resolutions

Port 80

Port 443

Subdomains